Advertisement

Dermatologic Adverse Events from Cancer Treatments

  • Jennifer Wu
  • Alina Markova
  • Mario E. LacoutureEmail author
Chapter

Abstract

The incidences of adverse events to cancer treatments have increased as new treatments are being developed. Dermatologic adverse events (dAEs) strongly impact patients’ quality of life (QoL). Severe dAEs can result in dose reduction or discontinuation, which may compromise clinical outcomes and even lead to life-threatening conditions. Prevention, early diagnosis, and proper management of dAEs are crucial for optimizing anticancer response and maintaining QoL. This chapter addresses dAEs induced by cytotoxic and targeted therapies, radiotherapy, stem cell transplantation, immunotherapies, and CAR-T cell therapy. Proposed underling mechanisms and recommended treatment approaches for these dAEs are presented.

Keywords

Dermatologic adverse event (dAE) Skin toxicity Chemotherapy Targeted therapy Immunotherapy Checkpoint inhibitor Immune-related adverse event (irAE) 

Abbreviations

ADL

Activities of daily living

ADRs

Adverse drug reactions

AGA

Androgenetic alopecia

AK

Actinic keratoses

CAR-T Cell

Chimeric antigen receptor-modified T lymphocytes

CIA

Chemotherapy-induced alopecia

CombiDT

Combination of dabrafenib with trametinib

CRS

Cytokine release syndrome

CTLA-4

Cytotoxic T lymphocyte antigen-4

DRESS

Drug reaction with eosinophilia and systemic symptoms

EGFR

Epidermal growth factor receptor

FAERS

Food and Drug Administration Adverse Event Reporting System

FEC

Fluorouracil/epirubicin/cyclophosphamide

GI

gastrointestinal

GVHD

Graft versus host disease

HFSR

Hand-foot skin reaction

HSCT

Hematopoietic stem cell transplantation

ICIs

Immune checkpoint inhibitors

IHSR

Immediate hypersensitivity reactions

irAEs

Immune-related adverse events

irBP

Immune-related bullous pemphigoid

JAKIs

Janus kinase inhibitors

KAs

Keratoacanthomas

MKIs

Multi-targeted kinase inhibitors

MMF

Mycophenolate mofetil

MPR

Maculopapular rash

MSSA

Methicillin-sensitive Staphylococcus aureus

nbUVB

Narrow band ultraviolet B

NSCLC

Non-small cell lung cancer

NV

Nasal vestibulitis

pCIA

persistent CIA

PLD

Pegylated liposomal doxorubicin

PPE

Papulopustular eruption

QoL

Quality of life

RD

Radiation dermatitis

SCARs

Severe cutaneous adverse reactions

SCCs

Squamous cell carcinomas

SCIs

Systemic calcineurin inhibitors

SJS/TEN

Stevens-Johnson syndrome/toxic epidermal necrolysis

SK

Seborrheic keratoses

TCIs

Topical calcineurin inhibitors

TCR

T cell receptor

WHO

World Health Organization

Notes

Acknowledgment

We would like to thank Ms. Bernadette Murphy for clinical photography.

References

  1. Aasi S, Silkiss R, Tang JY et al (2013) New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 149(2):242–243CrossRefPubMedPubMedCentralGoogle Scholar
  2. Abess A, Keel DM, Graham BS (2003) Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 139(3):337–339CrossRefPubMedPubMedCentralGoogle Scholar
  3. Aoyama T, Takano M, Miyamoto M et al (2017) Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? Cancer Chemother Pharmacol 80:65CrossRefPubMedPubMedCentralGoogle Scholar
  4. Asz-Sigall D, Gonzalez-de-Cossio-Hernandez AC, Rodriguez-Lobato E, Ortega-Springall MF, Vega-Memije ME, Arenas Guzman R (2016) Differential diagnosis of female-pattern hair loss. Skin Appendage Disord 2(1–2):18–21CrossRefPubMedPubMedCentralGoogle Scholar
  5. Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL (2011a) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Investig New Drugs 29(5):1114–1121CrossRefGoogle Scholar
  6. Balagula Y, Rosen ST, Lacouture ME (2011b) The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 65(3):624–635CrossRefPubMedPubMedCentralGoogle Scholar
  7. Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME (2012) The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investig New Drugs 30(4):1773–1781CrossRefGoogle Scholar
  8. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115(2):149–153CrossRefPubMedPubMedCentralGoogle Scholar
  9. Belum VR, Benhuri B, Postow MA et al (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12–25CrossRefPubMedPubMedCentralGoogle Scholar
  10. Belum VR, Cercek A, Sanz-Motilva V, Lacouture ME (2013c) Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. Curr Treat Options in Oncol 14(3):389–404CrossRefGoogle Scholar
  11. Belum VR, Fischer A, Choi JN, Lacouture ME (2013b) Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 15(3):249–259CrossRefPubMedPubMedCentralGoogle Scholar
  12. Belum VR, Fontanilla Patel H, Lacouture ME, Rodeck U (2013a) Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol 9(8):1161–1170CrossRefPubMedPubMedCentralGoogle Scholar
  13. Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME (2017) A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. J Am Acad Dermatol 77(3):577–579CrossRefPubMedPubMedCentralGoogle Scholar
  14. Belum VR, Marulanda K, Ensslin C et al (2015b) Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 26(12):2496–2502PubMedPubMedCentralGoogle Scholar
  15. Belum VR, Washington C, Pratilas CA, Sibaud V, Boralevi F, Lacouture ME (2015a) Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. Pediatr Blood Cancer 62(5):798–806CrossRefPubMedPubMedCentralGoogle Scholar
  16. Belum VR, Wu S, Lacouture ME (2013d) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Investig New Drugs 31(4):1078–1086CrossRefGoogle Scholar
  17. Betticher DC, Delmore G, Breitenstein U et al (2013) Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 21(9):2565–2573CrossRefPubMedPubMedCentralGoogle Scholar
  18. Bolognia JL, Cooper DL, Glusac EJ (2008) Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 59(3):524–529CrossRefPubMedPubMedCentralGoogle Scholar
  19. Brown J, Burck K, Black D, Collins C (1991) Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 24(6 Pt 1):1023–1025CrossRefPubMedPubMedCentralGoogle Scholar
  20. Burris HA 3rd, Hurtig J (2010) Radiation recall with anticancer agents. Oncologist 15(11):1227–1237CrossRefPubMedPubMedCentralGoogle Scholar
  21. Capriotti K, Capriotti JA, Lessin S et al (2015) The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol 173(3):842–845CrossRefPubMedPubMedCentralGoogle Scholar
  22. Capuano M, Sommese L, Pignalosa O et al (2015) Current clinical applications of extracorporeal photochemotherapy. Ther Apher Dial 19(2):103–110CrossRefPubMedPubMedCentralGoogle Scholar
  23. Carlos G, Anforth R, Clements A et al (2015) Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol 151(10):1103–1109CrossRefPubMedPubMedCentralGoogle Scholar
  24. Chandrakumar SF, Yeung J (2014) Cutaneous adverse events during vemurafenib therapy. J Cutan Med Surg 18(4):223–228CrossRefPubMedPubMedCentralGoogle Scholar
  25. Chen M, Chen J, Peng X et al (2017) The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol 49:81–88CrossRefPubMedPubMedCentralGoogle Scholar
  26. Chew L, Chuen VS (2009) Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 15(1):29–34CrossRefPubMedPubMedCentralGoogle Scholar
  27. Chittari K, Tagboto S, Tan BB (2009) Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation. Clin Exp Dermatol 34(3):405–406CrossRefPubMedPubMedCentralGoogle Scholar
  28. Choi JN (2014) Dermatologic adverse events to chemotherapeutic agents, part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg 33(1):40–48CrossRefPubMedPubMedCentralGoogle Scholar
  29. Clabbers JMK, Boers-Doets CB, Gelderblom H et al (2016) Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer 24(2):513–521CrossRefPubMedPubMedCentralGoogle Scholar
  30. Cook M, Johnson N, Zegzula HD, Schray M, Glissmeyer M, Sorenson L (2016) Prophylactic use of pentoxifylline (Trental) and vitamin E to prevent capsular contracture after implant reconstruction in patients requiring adjuvant radiation. Am J Surg 211(5):854–859CrossRefPubMedPubMedCentralGoogle Scholar
  31. Curry JL, Tetzlaff MT, Nagarajan P et al (2017) Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158–176CrossRefPubMedPubMedCentralGoogle Scholar
  32. Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76(4):736–744CrossRefPubMedPubMedCentralGoogle Scholar
  33. Dreno B, Ribas A, Larkin J et al (2017) Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 28(5):1137–1144CrossRefPubMedPubMedCentralGoogle Scholar
  34. Drilon A, Eaton AA, Schindler K et al (2016) Beyond the dose-limiting toxicity period: dermatologic adverse events of patients on phase 1 trials of the cancer therapeutics evaluation program. Cancer 122(8):1228–1237CrossRefPubMedPubMedCentralGoogle Scholar
  35. Elyasi S, Shojaee FSR, Allahyari A, Karimi G (2017) Topical Silymarin Administration for Prevention of Capecitabine-induced hand-foot syndrome: a randomized, double-blinded, placebo-controlled clinical trial. Phytother Res 31:1323CrossRefPubMedPubMedCentralGoogle Scholar
  36. Ensslin CJ, Rosen AC, Wu S, Lacouture ME (2013) Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 69(5):708–720CrossRefPubMedPubMedCentralGoogle Scholar
  37. European Medicines Agency (2016) European Public Assessment Report: Erivdege. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002602/WC500146821.pdf
  38. Fischer A, Wu S, Ho AL, Lacouture ME (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investig New Drugs 31(3):787–797CrossRefGoogle Scholar
  39. Fonia A, Cota C, Setterfield JF, Goldberg LJ, Fenton DA, Stefanato CM (2017) Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol 76:948CrossRefPubMedPubMedCentralGoogle Scholar
  40. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894CrossRefGoogle Scholar
  41. Gandhi M, Brieva JC, Lacouture ME (2014) Dermatologic infections in cancer patients. Cancer Treat Res 161:299–317CrossRefPubMedPubMedCentralGoogle Scholar
  42. Gelmon K (1994) The taxoids: paclitaxel and docetaxel. Lancet 344(8932):1267–1272CrossRefPubMedPubMedCentralGoogle Scholar
  43. Giavina-Bianchi P, Patil SU, Banerji A (2017) Immediate hypersensitivity reaction to chemotherapeutic agents. J Allergy Clin Immunol Pract 5(3):593–599CrossRefPubMedPubMedCentralGoogle Scholar
  44. Gilbar P, Hain A, Peereboom VM (2009) Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 15(3):143–155CrossRefPubMedPubMedCentralGoogle Scholar
  45. Glaser DA, Hossain P, Perkins W et al (2015) Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol 172(5):1384–1394CrossRefPubMedPubMedCentralGoogle Scholar
  46. Goldinger SM, Stieger P, Meier B et al (2016) Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 22(16):4023–4029CrossRefPubMedPubMedCentralGoogle Scholar
  47. Gomez P, Lacouture ME (2011) Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 16(11):1508–1519CrossRefPubMedPubMedCentralGoogle Scholar
  48. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Support Care Cancer 16(3):267–273CrossRefPubMedPubMedCentralGoogle Scholar
  49. Hofheinz RD, Deplanque G, Komatsu Y et al (2016) Recommendations for the prophylactic Management of Skin Reactions Induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Oncologist 21(12):1483–1491CrossRefPubMedPubMedCentralGoogle Scholar
  50. Hsiao YW, Lin YC, Hui RC, Yang CH (2011) Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma. J Clin Oncol 29(12):e340–e341CrossRefPubMedPubMedCentralGoogle Scholar
  51. Huang V, Anadkat M (2011) Dermatologic manifestations of cytotoxic therapy. Dermatol Ther 24(4):401–410CrossRefPubMedPubMedCentralGoogle Scholar
  52. Hymes SR, Alousi AM, Cowen EW (2012a) Graft-versus-host disease: part I Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol 66(4):515 e1–18; quiz 33–4CrossRefPubMedPubMedCentralGoogle Scholar
  53. Hymes SR, Alousi AM, Cowen EW (2012b) Graft-versus-host disease: part II Management of cutaneous graft-versus-host disease. J Am Acad Dermatol 66(4):535.e1–535.16 quiz 51–2CrossRefGoogle Scholar
  54. Ito J, Fujimoto D, Nakamura A et al (2017) Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 109:58–61CrossRefPubMedPubMedCentralGoogle Scholar
  55. Jain V, Bhandary S, Prasad GN, Shenoi SD (2005) Serpentine supravenous streaks induced by 5-fluorouracil. J Am Acad Dermatol 53(3):529–530CrossRefPubMedPubMedCentralGoogle Scholar
  56. Johnson DB, Wallender EK, Cohen DN et al (2013) Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 1(6):373–377CrossRefPubMedPubMedCentralGoogle Scholar
  57. Jour G, Glitza IC, Ellis RM et al (2016) Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 43(8):688–696CrossRefPubMedPubMedCentralGoogle Scholar
  58. Julia Dai VRB, Shenhong W, Sibaud V, Lacouture ME (2017) Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol 77(5):902–910.e2.  https://doi.org/10.1016/j.jaad.2017.06.044CrossRefPubMedPubMedCentralGoogle Scholar
  59. Keating GM (2016) Cobimetinib plus Vemurafenib: a review in BRAF (V600) mutation-positive unresectable or metastatic melanoma. Drugs 76(5):605–615CrossRefPubMedPubMedCentralGoogle Scholar
  60. Kluger N, Jacot W, Frouin E et al (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879–2884CrossRefPubMedPubMedCentralGoogle Scholar
  61. Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18(7):885–891CrossRefPubMedPubMedCentralGoogle Scholar
  62. Korman AM, Tyler KH, Kaffenberger BH (2017) Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma. Int J Dermatol 56(4):e75–ee7CrossRefPubMedPubMedCentralGoogle Scholar
  63. Kwong B, Danial C, Liu A, Chun KA, Chang AL (2017) Reversible cutaneous side effects of vismodegib treatment. Cutis 99(3):E19–e20PubMedPubMedCentralGoogle Scholar
  64. Kyllo RL, Anadkat MJ (2014a) Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxics, epidermal growth factor receptors, multikinase inhibitors, and proteasome inhibitors. Semin Cutan Med Surg 33(1):28–39CrossRefPubMedPubMedCentralGoogle Scholar
  65. Kyllo R, Anadkat M (2014b) Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxic agents, epidermal growth factor inhibitors, multikinase inhibitors, and proteasome inhibitors. Semin Cutan Med Surg 33(1):28–39CrossRefPubMedPubMedCentralGoogle Scholar
  66. Lacouture ME (2014) Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. John Wiley & Sons, Hoboken, NJGoogle Scholar
  67. Lacouture ME (2015) Management of dermatologic toxicities. J Natl Compr Canc Netw 13(5 Suppl):686–689CrossRefPubMedPubMedCentralGoogle Scholar
  68. Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095CrossRefPubMedPubMedCentralGoogle Scholar
  69. Lacouture ME, Ciccolini K, Kloos RT, Agulnik M (2014) Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Thyroid 24(9):1329–1340CrossRefPubMedPubMedCentralGoogle Scholar
  70. Lacouture ME, Dreno B, Ascierto PA et al (2016) Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 21(10):1218–1229CrossRefPubMedPubMedCentralGoogle Scholar
  71. Lacouture ME, Duvic M, Hauschild A et al (2013b) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18(3):314–322CrossRefPubMedPubMedCentralGoogle Scholar
  72. Lacouture ME, Maitland ML, Segaert S et al (2010a) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522CrossRefPubMedPubMedCentralGoogle Scholar
  73. Lacouture ME, Mitchell EP, Piperdi B et al (2010b) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351–1357CrossRefPubMedPubMedCentralGoogle Scholar
  74. Lacouture ME, Reilly LM, Gerami P, Guitart J (2008a) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19(11):1955–1961CrossRefPubMedPubMedCentralGoogle Scholar
  75. Lacouture ME, Schadendorf D, Chu CY et al (2013a) Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 13(6):721–728CrossRefPubMedPubMedCentralGoogle Scholar
  76. Lacouture ME, Wu S, Robert C et al (2008b) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9):1001–1011CrossRefPubMedPubMedCentralGoogle Scholar
  77. Langer SW (2010) Extravasation of chemotherapy. Curr Oncol Rep 12(4):242–246CrossRefPubMedPubMedCentralGoogle Scholar
  78. Larsabal M, Marti A, Jacquemin C et al (2017) Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 76:863CrossRefPubMedPubMedCentralGoogle Scholar
  79. Lindner J, Hillmann K, Blume-Peytavi U et al (2012) Hair shaft abnormalities after chemotherapy and tamoxifen therapy in patients with breast cancer evaluated by optical coherence tomography. Br J Dermatol 167(6):1272–1278CrossRefPubMedPubMedCentralGoogle Scholar
  80. Liu HB, Wu Y, Lv TF et al (2013) Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 8(1):e55128CrossRefPubMedPubMedCentralGoogle Scholar
  81. Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877–1888CrossRefPubMedGoogle Scholar
  82. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Ann Oncol 18(7):1159–1164CrossRefPubMedPubMedCentralGoogle Scholar
  83. LoRusso PM, Rudin CM, Reddy JC et al (2011) Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17(8):2502–2511CrossRefPubMedPubMedCentralGoogle Scholar
  84. Lou Y, Wang Q, Zheng J et al (2016) Possible pathways of Capecitabine-induced hand-foot syndrome. Chem Res Toxicol 29(10):1591–1601CrossRefPubMedPubMedCentralGoogle Scholar
  85. Macedo LT, Lima JP, dos Santos LV, Sasse AD (2014) Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 22(6):1585–1593PubMedPubMedCentralGoogle Scholar
  86. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E (2008) Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 108(2):332–335CrossRefPubMedPubMedCentralGoogle Scholar
  87. McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E (2015) Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26(10):2017–2026CrossRefPubMedPubMedCentralGoogle Scholar
  88. Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148CrossRefPubMedPubMedCentralGoogle Scholar
  89. Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P, Tosti A (2011) Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol 33(4):345–350CrossRefPubMedPubMedCentralGoogle Scholar
  90. Naidoo J, Schindler K, Querfeld C et al (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4(5):383–389CrossRefPubMedPubMedCentralGoogle Scholar
  91. Nangia J, Wang T, Osborne C et al (2017) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 317(6):596–605CrossRefPubMedPubMedCentralGoogle Scholar
  92. Nayar N, Briscoe K, Fernandez Penas P (2016) Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with Nivolumab in a patient with Ipilimumab refractory metastatic melanoma. J Immunother 39(3):149–152CrossRefPubMedPubMedCentralGoogle Scholar
  93. Nikolaou V, Syrigos K, Saif MW (2016) Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 15(12):1625–1633CrossRefPubMedPubMedCentralGoogle Scholar
  94. Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A (2011) Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol 64(3):604–606CrossRefPubMedPubMedCentralGoogle Scholar
  95. Park HJ, Lee JH, Kim SR et al (2016) A new practical desensitization protocol for Oxaliplatin-induced immediate hypersensitivity reactions: a necessary and useful approach. J Investig Allergol Clin Immunol 26(3):168–176CrossRefPubMedPubMedCentralGoogle Scholar
  96. Parker TL, Cooper DL, Seropian SE, Bolognia JL (2013) Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplant 48(5):646–650CrossRefPubMedPubMedCentralGoogle Scholar
  97. Prevezas C, Matard B, Pinquier L, Reygagne P (2009) Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 160(4):883–885CrossRefPubMedPubMedCentralGoogle Scholar
  98. Pugliese SB, Neal JW, Kwong BY (2015) Management of Dermatologic Complications of lung Cancer therapies. Curr Treat Options in Oncol 16(10):50CrossRefGoogle Scholar
  99. Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG (2015) Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev 12:CD011552Google Scholar
  100. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521–2532CrossRefPubMedPubMedCentralGoogle Scholar
  101. Rosen AC, Balagula Y, Raisch DW et al (2014) Life-threatening dermatologic adverse events in oncology. Anti-Cancer Drugs 25(2):225–234CrossRefPubMedPubMedCentralGoogle Scholar
  102. Rugo HS, Melin SA, Voigt J (2017) Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat 163(2):199–205CrossRefPubMedPubMedCentralGoogle Scholar
  103. Ruiz JN, Belum VR, Boers-Doets CB et al (2015) Nasal vestibulitis due to targeted therapies in cancer patients. Support Care Cancer 23(8):2391–2398CrossRefPubMedPubMedCentralGoogle Scholar
  104. Saif MW, Katirtzoglou NA, Syrigos KN (2008) Capecitabine: an overview of the side effects and their management. Anti-Cancer Drugs 19(5):447–464PubMedPubMedCentralGoogle Scholar
  105. Sanborn RE, Sauer DA (2008) Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin 26(1):103–119 ixCrossRefPubMedPubMedCentralGoogle Scholar
  106. Santoni M, Conti A, Andrikou K et al (2015) Risk of pruritus in cancer patients treated with biological therapies: a systematic review and meta-analysis of clinical trials. Crit Rev Oncol Hematol 96(2):206–219CrossRefPubMedGoogle Scholar
  107. Scotte F, Banu E, Medioni J et al (2008) Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 112(7):1625–1631CrossRefPubMedGoogle Scholar
  108. Scotte F, Tourani JM, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23(19):4424–4429CrossRefPubMedGoogle Scholar
  109. Sekulic A, Migden MR, Basset-Seguin N et al (2017) Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 17(1):332CrossRefPubMedPubMedCentralGoogle Scholar
  110. Sekulic A, Migden MR, Oro AE et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171–2179CrossRefPubMedPubMedCentralGoogle Scholar
  111. Shaitelman SF, Schlembach PJ, Arzu I et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 1(7):931–941CrossRefPubMedPubMedCentralGoogle Scholar
  112. Shreberk-Hassidim R, Ramot Y, Zlotogorski A (2017) Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol 76(4):745–753 e19CrossRefPubMedPubMedCentralGoogle Scholar
  113. Sibaud V, Eid C, Belum VR et al (2017) Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol 31:e464CrossRefPubMedPubMedCentralGoogle Scholar
  114. Sibaud V, Leboeuf NR, Roche H et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26(5):427–443PubMedPubMedCentralGoogle Scholar
  115. Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR (2017) Rituximab treatment of Nivolumab-induced bullous pemphigoid. JAMA Dermatol 153(6):603–605CrossRefPubMedPubMedCentralGoogle Scholar
  116. Spanemberg JC, Figueiredo MA, Cherubini K, Salum FG (2016) Low-level laser therapy: a review of its applications in the management of oral mucosal disorders. Altern Ther Health Med 22(6):24–31PubMedPubMedCentralGoogle Scholar
  117. Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA (2010) Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 5(6):e10968CrossRefPubMedPubMedCentralGoogle Scholar
  118. Suvirya S, Agrawal A, Parihar A (2014) 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. BMJ Case Rep 2014:bcr2014206793CrossRefPubMedPubMedCentralGoogle Scholar
  119. Syrigou E, Dannos I, Kotteas E et al (2011) Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 156(3):320–324CrossRefPubMedPubMedCentralGoogle Scholar
  120. Tallon B, Blanchard E, Goldberg LJ (2010) Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 63(2):333–336CrossRefPubMedPubMedCentralGoogle Scholar
  121. Tanaka R, Fujisawa Y, Sae I et al (2017) Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Jpn J Clin Oncol 47(2):175–178CrossRefPubMedPubMedCentralGoogle Scholar
  122. Tang N, Ratner D (2016) Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer. Dermatol Surg 42(Suppl 1):S40–S48CrossRefPubMedPubMedCentralGoogle Scholar
  123. Teresi ME, Murry DJ, Cornelius AS (1993) Ifosfamide-induced hyperpigmentation. Cancer 71(9):2873–2875CrossRefPubMedPubMedCentralGoogle Scholar
  124. Tischer B, Huber R, Kraemer M, Lacouture ME (2017) Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer 25(2):651–660CrossRefPubMedPubMedCentralGoogle Scholar
  125. Trueb RM (2007) Chemotherapy-induced anagen effluvium: diffuse or patterned? Dermatology (Basel, Switzerland) 215(1):1–2CrossRefGoogle Scholar
  126. Trueb RM (2010) Chemotherapy-induced hair loss. Skin Therapy Lett 15(7):5–7PubMedPubMedCentralGoogle Scholar
  127. US (2012) Food and Drug Administration Web site. Vismodegib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf. Accessed 26 June 2017
  128. Valentine J, Belum VR, Duran J et al (2015) Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol 72(4):656–667CrossRefPubMedPubMedCentralGoogle Scholar
  129. van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20(12):3255–3260CrossRefPubMedPubMedCentralGoogle Scholar
  130. Villarreal CD, Alanis JC, Perez JC, Candiani JO (2016) Cutaneous graft-versus-host disease after hematopoietic stem cell transplant – a review. An Bras Dermatol 91(3):336–343CrossRefPubMedPubMedCentralGoogle Scholar
  131. Vincenzi B, Tonini G, Santini D (2010) Aprepitant for erlotinib-induced pruritus. N Engl J Med 363(4):397–398CrossRefPubMedPubMedCentralGoogle Scholar
  132. von Moos R, Thuerlimann BJ, Aapro M et al (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44(6):781–790CrossRefGoogle Scholar
  133. Voskens CJ, Goldinger SM, Loquai C et al (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8(1):e53745CrossRefPubMedPubMedCentralGoogle Scholar
  134. Vuerstaek JD, Frank J, Poblete-Gutierrez P (2007) Bleomycin-induced flagellate dermatitis. Int J Dermatol 46(Suppl 3):3–5CrossRefPubMedPubMedCentralGoogle Scholar
  135. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS, Investigators MDX (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119(9):1675–1682CrossRefPubMedPubMedCentralGoogle Scholar
  136. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697CrossRefGoogle Scholar
  137. Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092–2099CrossRefPubMedPubMedCentralGoogle Scholar
  138. Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164CrossRefPubMedPubMedCentralGoogle Scholar
  139. Wolff D, Ayuk F, Elmaagacli A et al (2013) Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant 19(5):767–776CrossRefPubMedPubMedCentralGoogle Scholar
  140. Wong RK, Bensadoun RJ, Boers-Doets CB et al (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC skin toxicity study group. Support Care Cancer 21(10):2933–2948CrossRefPubMedPubMedCentralGoogle Scholar
  141. Wu J, Lee YY, Su SC et al (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br J Dermatol 173(5):1224–1231CrossRefPubMedPubMedCentralGoogle Scholar
  142. Wyatt AJ, Leonard GD, Sachs DL (2006) Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 7(1):45–63CrossRefPubMedPubMedCentralGoogle Scholar
  143. Yeh CN, Chung WH, Su SC et al (2014) Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction. J Invest Dermatol 134(11):2768–2775CrossRefPubMedPubMedCentralGoogle Scholar
  144. Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23(5):1348–1353CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jennifer Wu
    • 1
    • 2
    • 3
  • Alina Markova
    • 1
  • Mario E. Lacouture
    • 1
    Email author
  1. 1.Dermatology Service, Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Dermatology, Drug Hypersensitivity Clinical and Research CenterChang Gung Memorial HospitalTaipeiTaiwan
  3. 3.College of MedicineChang Gung UniversityTaoyuanTaiwan

Personalised recommendations